Skip to main content
. 2018 Jun 1;29(2):101–112. doi: 10.1089/humc.2017.143

Figure 2.

Figure 2.

eqIL-1Ra content and AAV2.5 neutralizing antibody (NAb) in recovered biological fluids. (a) Mean eqIL-1Ra levels in synovial fluid of the OCF joints from the treated and control groups (n = 10). The dashed line reflects mean AAV.eqIL-1Ra expression in healthy joints from the same viral dose.15 For (a–f), the week 0 values represent baseline levels in the respective biological fluids collected immediately before injection of vector (treated group) or the Lactated Ringer's solution vehicle (control group) (b) Synovial fluid eqIL-1Ra in the OCF joint of the individual horses in the treated group. Each color reflects a different animal. (c) Mean eqIL-1Ra in urine for both the treated and control groups (n = 10). (d) Mean eqIL-1Ra in serum from peripheral blood for 9/10 animals in both the treated and control groups. (e) eqIL-1Ra in blood serum from the remaining horses (one each from the treated and control groups), which prior to treatment were >25 × greater than the other 18 animals in the study. (f) AAV.2.5 NAb titers in synovial fluids of the OCF joints and peripheral blood serum and of the horses in the treated group (n = 10). Error bars represent ±standard error of the mean (SEM). *p < 0.05.